Anti-HER2 Antibody-drug Conjugate BL-M07D1: all 21 studies that test it
Page 1 of 1. Open to participants first (17), then studies with results posted, then the rest; newest registration first within each.
- BL-M07D1 (Trastuzumab Brengitecan T-bren) vs Standard of Care Platinum-based Chemotherapy (PBC) for HER2-expressing Metastatic Urothelial Cancer After Progression on Anti-PD-(L)1-based TherapyRecruitingNCT07869836Phase 3
- A Study Comparing BL-M07D1 With Physician's Choice Therapy in Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Failed Prior Treatment With Oxaliplatin, Fluorouracil and IrinotecanNot yet recruitingNCT07730489Phase 3
- A Study Comparing BL-M07D1 With DS-8201 in Patients With HR-Positive, HER2-Low Expressing Recurrent/Metastatic Breast CancerRecruitingNCT07678957Phase 2
- A Study of BL-M07D1 Versus Physician's Choice of Chemotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Biliary Tract Cancer After Platinum-containing Chemotherapy FailureRecruitingNCT07606599Phase 3
- A Study Comparing BL-M07D1 With Physician's Choice of Chemotherapy in Patients With HER2-Expressing Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal CancerNot yet recruitingNCT07545460Phase 3
- A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or Metastatic Breast CancerRecruitingNCT07518173Phase 3
- A Study of BL-M07D1 in Combination With Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic HER2-Overexpressing Non-Squamous NSCLCRecruitingNCT07264816Phase 2
- A Study of BL-M07D1 vs Pembrolizumab-platinum Chemotherapy in First-line Treatment of HER2-mutant Advanced or Metastatic Non-squamous NSCLCRecruitingNCT07178795Phase 3
- A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-positive Locally Advanced or Metastatic Gastric or Gastro-esophageal Junction AdenocarcinomaRecruitingNCT07152405Phase 3
- A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast CancerRecruitingNCT06957886Phase 3
- A Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast CancerRecruitingNCT06891833Phase 2/3
- A Study of BL-M07D1 Versus T-DM1 in the Adjuvant Treatment of HER2-positive Breast Cancer With Residual Invasive Cancer After Neoadjuvant TherapyRecruitingNCT06830889Phase 3
- Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid TumorsRecruitingNCT06293898Phase 1
- A Study of BL-M07D1 in Patients With Recurrent or Metastatic Gynecologic MalignanciesRecruitingNCT06131450Phase 1/2
- A Study of BL-M07D1 in Patients With a Variety of Solid Tumors Including Locally Advanced or Metastatic HER2-positive/Low-expressing Urinary and Gastrointestinal TumorsRecruitingNCT06031584Phase 1/2
- Phase I Clinical Study of BL-M07D1 in Locally Advanced or Metastatic Digestive Tract Tumors and Other Solid TumorsRecruitingNCT05631964Phase 1
- A Study of BL-M07D1 in Patients With Locally Advanced or Metastatic HER2-Positive/Negative Breast Cancer and Other Solid TumorsRecruitingNCT05461768Phase 1
- A Study of BL-M07D1, BL-M07D1+Pertuzumab and BL-M07D1+Pertuzumab+Docetaxel in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast CancerActive, not recruitingNCT06445400Phase 2
- A Study of BL-M07D1 Combination Therapy in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction AdenocarcinomaActive, not recruitingNCT06423885Phase 2
- A Study Comparing BL-M07D1 With T-DM1 in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast CancerActive, not recruitingNCT06316531Phase 3
- A Study of BL-M07D1 in Patients With HER2-Overexpressing or HER2-Mutant Locally Advanced or Metastatic Non-Small Cell Lung CancerActive, not recruitingNCT06114511Phase 1/2